Citigroup reissued their buy rating on shares of Shire (LON:SHP) in a research report report published on Friday. The firm currently has a GBX 5,500 ($74.02) price target on the biopharmaceutical company’s stock.
A number of other research analysts have also commented on SHP. J P Morgan Chase & Co lowered their price target on Shire from GBX 5,500 ($74.02) to GBX 5,300 ($71.33) and set an overweight rating for the company in a research report on Wednesday, September 13th. Goldman Sachs Group reaffirmed a conviction-buy rating on shares of Shire in a research report on Tuesday, October 17th. Liberum Capital reaffirmed a hold rating and set a GBX 4,400 ($59.22) price target on shares of Shire in a research report on Tuesday, October 3rd. Deutsche Bank lowered their price target on Shire from GBX 6,000 ($80.75) to GBX 5,700 ($76.72) and set a buy rating for the company in a research report on Tuesday, September 5th. Finally, Barclays lowered Shire to an equal weight rating in a research report on Friday, August 11th. Four equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of GBX 5,277.78 ($71.03).
Shares of Shire (LON:SHP) opened at GBX 3,718 ($50.04) on Friday. Shire has a fifty-two week low of GBX 3,435.50 ($46.24) and a fifty-two week high of GBX 5,067 ($68.20).
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://weekherald.com/2017/12/12/citigroup-reiterates-buy-rating-for-shire-shp.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.